Neutralizing monoclonal antibodies as promising therapeutics against middle east respiratory syndrome coronavirus infection

Viruses

Volumn 10, Issue 12, 2018, Pages

  Han, Hui Ju ^a   Liu, Jian Wei ^a   Yu, Hao ^b   Yu, Xue Jie ^a  

^a WUHAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

MERS CoV; Middle East Respiratory Syndrome Virus; Neutralizing monoclonal antibodies

Indexed keywords

2 E6; 3 B11; 4 C2; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; EPITOPE; HCAB 83; IMMUNOGLOBULIN G; LCA 60; LYMPHOCYTE ANTIBODY; M 336; MCA 1; MERS 27; MERS 4; MERS GD 27; MERS GD 33; MERSMAB1; MONOCLONAL ANTIBODY; NANOBODY; NBMS 10; NBMS 10FC; NEUTRALIZING ANTIBODY; REGN 3048; REGN 3051; SINGLE STRANDED RNA; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS SPIKE PROTEIN; VITRONECTIN; ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIBODY SECRETING CELL; COMPETITIVE BINDING ASSAY; COST EFFECTIVENESS ANALYSIS; CRYSTAL STRUCTURE; DISEASE SEVERITY; DNA LIBRARY; GENE MUTATION; HUMAN; HYBRIDOMA CELL LINE; IMMUNOTHERAPY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY RATE; NONHUMAN; PERMEABILITY; RECEPTOR BINDING; REVIEW; SPLEEN CELL; TRANSGENIC MOUSE; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CAMEL; CORONAVIRUS INFECTION; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CAMELUS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR TARGETED THERAPY; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES;

EID: 85058278105     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v10120680     Document Type: Review

References (48)

1. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.M.E.; Fouchier, R.A.M. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367, 1814–1820. [CrossRef] [PubMed]
2. Han, H.J.; Yu, H.; Yu, X.J. Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus. J. Gen. Virol. 2016, 97, 274–280. [CrossRef] [PubMed]
3. Hui, D.S.; Azhar, E.I.; Kim, Y.J.; Memish, Z.A.; Oh, M.D.; Zumla, A. Middle East respiratory syndrome coronavirus: Risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect. Dis. 2018, 18, E217–E227. [CrossRef]
4. Lee, S.S.; Wong, N.S. Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea. Int. J. Infect. Dis. 2015, 38, 65–67. [CrossRef] [PubMed]
5. Jin, Y.J.; Lei, C.; Hu, D.; Dimitrov, D.S.; Ying, T.L. Human monoclonal antibodies as candidate therapeutics against emerging viruses. Front. Med. 2017, 11, 462–470. [CrossRef] [PubMed]
6. Van Boheemen, S.; de Graaf, M.; Lauber, C.; Bestebroer, T.M.; Raj, V.S.; Zaki, A.M.; Osterhaus, A.D.M.E.; Haagmans, B.L.; Gorbalenya, A.E.; Snijder, E.J. et al. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans. mBio 2012, 3, e00473-12. [CrossRef] [PubMed]
7. Du, L.Y.; Yang, Y.; Zhou, Y.S.; Lu, L.; Li, F.; Jiang, S.B. MERS-CoV spike protein: A key target for antivirals. Expert Opin. Ther. Targets 2017, 21, 131–143. [CrossRef] [PubMed]
8. Wang, N.S.; Shi, X.L.; Jiang, L.W.; Zhang, S.Y.; Wang, D.L.; Tong, P.; Guo, D.X.; Fu, L.L.; Cui, Y.; Liu, X.; et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013, 23, 986–993. [CrossRef] [PubMed]
9. Raj, V.S.; Mou, H.H.; Smits, S.L.; Dekkers, D.H.W.; Muller, M.A.; Dijkman, R.; Muth, D.; Demmers, J.A.A.; Zaki, A.; Fouchier, R.A.M.; et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495, 251–254. [CrossRef] [PubMed]
10. Li, Y.; Wan, Y.H.; Liu, P.P.; Zhao, J.C.; Lu, G.W.; Qi, J.X.; Wang, Q.H.; Lu, X.C.; Wu, Y.; Liu, W.J.; et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 2015, 25, 1237–1249. [CrossRef] [PubMed]
11. Du, L.Y.; Zhao, G.Y.; Yang, Y.; Qiu, H.J.; Wang, L.L.; Kou, Z.H.; Tao, X.R.; Yu, H.; Sun, S.H.; Tseng, C.T.K.; et al. A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein. J. Virol. 2014, 88, 7045–7053. [CrossRef] [PubMed]
12. Tang, X.C.; Agnihothram, S.S.; Jiao, Y.J.; Stanhope, J.; Graham, R.L.; Peterson, E.C.; Avnir, Y.; Tallarico, A.S.; Sheehan, J.; Zhu, Q.; et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. USA 2014, 111, 6863. [CrossRef] [PubMed]
13. Johnson, R.F.; Bagci, U.; Keith, L.; Tang, X.C.; Mollura, D.J.; Zeitlin, L.; Qin, J.; Huzella, L.; Bartos, C.J.; Bohorova, N.; et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 2016, 490, 49–58. [CrossRef] [PubMed]
14. Ying, T.L.; Du, L.Y.; Ju, T.W.; Prabakaran, P.; Lau, C.C.Y.; Lu, L.; Liu, Q.; Wang, L.L.; Feng, Y.; Wang, Y.P.; et al. Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. J. Virol. 2014, 88, 7796–7805. [CrossRef] [PubMed]
15. Houser, K.V.; Gretebeck, L.; Ying, T.L.; Wang, Y.P.; Vogel, L.; Lamirande, E.W.; Bock, K.W.; Moore, I.N.; Dimitrov, D.S.; Subbarao, K. Prophylaxis with a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. J. Infect. Dis. 2016, 213, 1557–1561. [CrossRef] [PubMed]
16. Agrawal, A.S.; Ying, T.L.; Tao, X.R.; Garron, T.; Algaissi, A.; Wang, Y.P.; Wang, L.L.; Peng, B.H.; Jiang, S.B.; Dimitrov, D.S.; et al. Passive Transfer of a Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci. Rep. 2016, 6, 31629. [CrossRef] [PubMed]
17. Van Doremalen, N.; Falzarano, D.; Ying, T.L.; de Wit, E.; Bushmaker, T.; Feldmann, F.; Okumura, A.; Wang, Y.; Scott, D.P.; Hanley, P.W.; et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antivir. Res. 2017, 143, 30–37. [CrossRef] [PubMed]
18. Corti, D.; Zhao, J.C.; Pedotti, M.; Simonelli, L.; Agnihothram, S.; Fett, C.; Fernandez-Rodriguez, B.; Foglierini, M.; Agatic, G.; Vanzetta, F.; et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. USA 2015, 112, 10473–10478. [CrossRef] [PubMed]
19. Zhao, J.C.; Li, K.; Wohlford-Lenane, C.; Agnihothram, S.S.; Fett, C.; Zhao, J.X.; Gale, M.J.; Baric, R.S.; Enjuanes, L.; Gallagher, T.; et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 2014, 111, 4970–4975. [CrossRef] [PubMed]
20. Corti, D.; Passini, N.; Lanzavecchia, A.; Zambon, M. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J. Infect. Public Health 2016, 9, 231–235. [CrossRef] [PubMed]
21. Pascal, K.E.; Coleman, C.M.; Mujica, A.O.; Kamat, V.; Badithe, A.; Fairhurst, J.; Hunt, C.; Strein, J.; Berrebi, A.; Sisk, J.M. et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA 2015, 112, 8738–8743. [CrossRef] [PubMed]
22. De Wit, E.; Feldmann, F.; Okumura, A.; Horne, E.; Haddock, E.; Saturday, G.; Scott, D.; Erlandson, K.J.; Stahl, N.; Lipsich, L.; et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antivir. Res. 2018, 156, 64–71. [CrossRef] [PubMed]
23. Chen, Z.; Bao, L.L.; Chen, C.; Zou, T.T.; Xue, Y.; Li, F.D.; Lv, Q.; Gu, S.Z.; Gao, X.P.; Cui, S.; et al. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset. J. Infect. Dis. 2017, 215, 1807–1815. [CrossRef] [PubMed]
24. Jiang, L.W.; Wang, N.S.; Zuo, T.; Shi, X.L.; Poon, K.M.V.; Wu, Y.K.; Gao, F.; Li, D.Y.; Wang, R.K.; Guo, J.Y.; et al. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. Sci. Transl. Med. 2014, 6, 234ra59. [CrossRef] [PubMed]
25. Zhang, S.Y.; Zhou, P.P.; Wang, P.F.; Li, Y.Y.; Jiang, L.W.; Jia, W.X.; Wang, H.; Fan, A.; Wang, D.L.; Shi, X.L. et al. Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. Cell Rep. 2018, 24, 441–452. [CrossRef] [PubMed]
26. Niu, P.; Zhang, S.; Zhou, P.; Huang, B.; Deng, Y.; Qin, K.; Wang, P.; Wang, W.; Wang, X.; Zhou, J.; et al. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus from a Recovered Patient. J. Infect. Dis. 2018, 218, 1249–1260. [CrossRef] [PubMed]
27. Niu, P.; Zhao, G.; Deng, Y.; Sun, S.; Wang, W.; Zhou, Y.; Tan, W. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice. Sci. China Life Sci. 2018, 61, 1280–1282. [CrossRef] [PubMed]
28. Hamers-casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Bendahman, N.; Hamers, R. Naturally-Occurring Antibodies Devoid of Light-Chains. Nature 1993, 363, 446–448. [CrossRef] [PubMed]
29. De Genst, E.; Silence, K.; Decanniere, K.; Conrath, K.; Loris, R.; Kinne, J.; Muyldermans, S.; Wyns, L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. USA 2016, 103, 4586–4591. [CrossRef] [PubMed]
30. Muyldermans, S. Nanobodies: Natural Single-Domain Antibodies. Annu. Rev. Biochem. 2013, 82, 775–797. [CrossRef] [PubMed]
31. Wilken, L.; McPherson, A. Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections. Int. Rev. Immunol. 2018, 37, 69–76. [CrossRef] [PubMed]
32. Van Heeke, G.; Allosery, K.; De Brabandere, V.; De Smedt, T.; Detalle, L. de Fougerolles, A. Nanobodies(R) as inhaled biotherapeutics for lung diseases. Pharmacol. Ther. 2017, 169, 47–56. [CrossRef] [PubMed]
33. Detalle, L.; Stohr, T.; Palomo, C.; Piedra, P.A.; Gilbert, B.E.; Mas, V.; Millar, A.; Power, U.F.; Stortelers, C.; Allosery, K.; et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob. Agents Chemother. 2016, 60, 6–13. [CrossRef] [PubMed]
34. Stalin Raj, V.; Okba, N.M.A.; Gutierrez-Alvarez, J.; Drabek, D.; van Dieren, B.; Widagdo, W.; Lamers, M.M.; Widjaja, I.; Fernandez-Delgado, R.; Sola, I.; et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Sci. Adv. 2018, 4, eaas9667. [CrossRef] [PubMed]
35. Lu, G.W.; Hu, Y.W.; Wang, Q.H.; Qi, J.X.; Gao, F.; Li, Y.; Zhang, Y.F.; Zhang, W.; Yuan, Y.; Bao, J.K.; et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500, 227. [CrossRef] [PubMed]
36. Zhao, G.; He, L.; Sun, S.; Qiu, H.; Tai, W.; Chen, J.; Li, J.; Chen, Y.; Guo, Y.; Wang, Y. et al. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J. Virol. 2018, 92, e00837-18. [CrossRef] [PubMed]
37. Wang, L.; Shi, W.; Chappell, J.D.; Joyce, M.G.; Zhang, Y.; Kanekiyo, M.; Becker, M.M.; van Doremalen, N.; Fischer, R.; Wang, N.; et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. J. Virol. 2018. [CrossRef]
38. Bermingham, A.; Chand, M.A.; Brown, C.S.; Aarons, E.; Tong, C.; Langrish, C.; Hoschler, K.; Brown, K.; Galiano, M.; Myers, R.; et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Eurosurveillance 2012, 17, 20290. [PubMed]
39. Song, W.F.; Wang, Y.; Wang, N.S.; Wang, D.L.; Guo, J.Y.; Fu, L.L.; Shi, X.L. Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry. Virology 2014, 471, 49–53. [CrossRef] [PubMed]
40. Chen, Y.Z.; Lu, S.; Jia, H.; Deng, Y.; Zhou, J.F.; Huang, B.Y.; Yu, Y.Y.; Lan, J.M.; Wang, W.L.; Lou, Y.L.; et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg. Microbes Infect. 2017, 6, e37. [CrossRef] [PubMed]
41. Coleman, C.M.; Matthews, K.L.; Goicochea, L.; Frieman, M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 2014, 95, 408–412. [CrossRef] [PubMed]
42. De Wit, E.; Prescott, J.; Baseler, L.; Bushmaker, T.; Thomas, T.; Lackemeyer, M.G.; Martellaro, C.; Milne-Price, S.; Haddock, E.; Haagmans, B.L.; et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 2013, 8, e69127. [CrossRef] [PubMed]
43. Raj, V.S.; Smits, S.L.; Provacia, L.B.; van den Brand, J.M.; Wiersma, L.; Ouwendijk, W.J.; Bestebroer, T.M.; Spronken, M.I.; van Amerongen, G.; Rottier, P.J.; et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 2014, 88, 1834–1838. [CrossRef] [PubMed]
44. Haagmans, B.L.; van den Brand, J.M.A.; Provacia, L.B.; Raj, V.S.; Stittelaar, K.J.; Getu, S.; de Waal, L.; Bestebroer, T.M.; van Amerongen, G.; Verjans, G.M.G.M.; et al. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits. J. Virol. 2015, 89, 6131–6135. [CrossRef] [PubMed]
45. Haverkamp, A.K.; Lehmbecker, A.; Spitzbarth, I.; Widagdo, W.; Haagmans, B.L.; Segales, J.; Vergara-Alert, J.; Bensaid, A.; van den Brand, J.M.A.; Osterhaus, A.; et al. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4. Sci. Rep. 2018, 8, 9778. [CrossRef] [PubMed]
46. Yao, Y.; Bao, L.; Deng, W.; Xu, L.; Li, F.; Lv, Q.; Yu, P.; Chen, T.; Xu, Y.; Zhu, H.; et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 2014, 209, 236–242. [CrossRef] [PubMed]
47. Falzarano, D.; de Wit, E.; Feldmann, F.; Rasmussen, A.L.; Okumura, A.; Peng, X.X.; Thomas, M.J.; van Doremalen, N.; Haddock, E.; Nagy, L.; et al. Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset. PLoS Pathog. 2014, 10, e1004250. [CrossRef] [PubMed]
48. Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; et al. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS ONE 2015, 10, e0145561. [CrossRef] [PubMed]